ZYBERNO
Stock Report
Updated May 31, 2026

Verona Pharma plc (VRNA)

Healthcare • NASDAQ

$106.91
Verona Pharma plc is a British biopharmaceutical company headquartered in London, England, that develops inhaled treatments for respiratory diseases. The company's lead product ensifentrine (brand name Ohtuvayre) was approved by the FDA in 2024 as the first inhaled dual PDE3 and PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease (COPD), representing a new mechanism of action in respiratory medicine.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
24.0/100
POOR BUSINESS
Verona Pharma plc (VRNA) scores 24/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-38.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-50.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Verona Pharma plc (VRNA) stock report — Zyberno Score 24/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VRNA generated -$120.74M in Owner Earnings. Capital was deployed as follows: $1.10M invested in capital expenditures. Reinvestment rate: 1.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:106.91
Market Cap:$9.16B

Valuation Multiples (2)

P/B Ratio:32.90x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.96B
B. Profitability Assessment

Return Metrics (5)

ROA:-16.6%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-0.6%

Margin Analysis (1)

Ebitda Margin:-129.9%

Yield Metrics (2)

Earnings Yield:-$0.01
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:208.3%
Latest Earnings Filed:2025-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):10.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.71x
Quick Ratio:10.54x
Cash Ratio:8.55x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.15x
Times Interest Earned:-4.15

Capital Structure (4)

Working Capital:497,613,000.00
Cash And Cash Equivalents:438,016,000.00
Long Term Debt:$242.43M
Net Debt:-$194.57M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $42.28M
Linear Growth: 10.1%
📊 Click to view full VRNA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$56.02M

Bottom Line Performance (3)

-$81.19M
Income Before Tax:-$72.94M
Ebitda Ttm:-54,928,000.00

Operating Expenses (5)

Operating Expenses:277,691,000.00
R And D Expense:46,452,000.00
Sga Expense:221,520,000.00
Income Tax Expense:$8.24M
Interest Expense:37,216,000.00

Expense Ratios (3)

R And D To Revenue Percentage:45.0%
Sga To Revenue Percentage:214.8%
Ebitda Margin:-129.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$572.87M
Current Assets:$548.85M
Ppe Net:991,000.00
Goodwill:545,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:294,598,000.00
Current Liabilities:51,238,000.00
Long Term Debt:$242.43M
Short Term Debt:$1.01M

Equity & Capital (3)

Equity:$278.27M
Retained Earnings:-$567.10M
Common Stock:45,021,000.00

Working Capital Items (3)

Accounts Receivable:82,858,000.00
Inventory:8,612,000.00
Accounts Payable:43,328,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:34,814,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$120.15M-$121.25M

Investment Activities (2)

Investing Cash Flow:-$535.00K
Capital Expenditures Ttm:1,099,000.00

Financing Activities (3)

Financing Cash Flow:$13.46M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:97,496,000.00
Long Term Debt Issuance:$122.50M
Long Term Debt Repayments:$52.26M

Non-Cash Items (1)

Depreciation Amortization Ttm:1,090,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):0.00
-$0.01
Earnings Per Share Ttm:-$0.95

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.49
Operating Cash Flow Per Share:-$1.43

Book Value & Capital (2)

Book Value Per Share:$3.25
Cash Per Share:5.11

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.09x
Working Capital Turnover Ttm:0.08x

Receivables Management (2)

Receivables Turnover Ttm:0.51x
Days Sales Outstanding Ttm:715.32

Inventory Management (2)

Inventory Turnover Ttm:4.91x
Days Inventory Outstanding Ttm:74.35

Payables & Cash Cycle (2)

Days Payable Outstanding:374.06
Cash Conversion Cycle:415.62
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$120.74M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-0.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):10.1%

Other Growth Rates (1)

Book Value Growth Rate (Linear):9.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:VRNA
Company Name:Verona Pharma plc
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:85.64M
Shares Outstanding Basic:685.16M
Shares Outstanding Diluted:727.22M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-05-31 11:07:44 UTC
Data Timestamp:2026-05-31T11:07:44.623395
Scroll to Top